CN102688479A - Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask - Google Patents
Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask Download PDFInfo
- Publication number
- CN102688479A CN102688479A CN2012102045578A CN201210204557A CN102688479A CN 102688479 A CN102688479 A CN 102688479A CN 2012102045578 A CN2012102045578 A CN 2012102045578A CN 201210204557 A CN201210204557 A CN 201210204557A CN 102688479 A CN102688479 A CN 102688479A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- cell growth
- gamma
- polyglutamic acid
- xerophthalmia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a composition for preventing xerophthalmia, an eye mask with the composition and a preparation method of the eye mask. The composition comprises an effective dosage of gamma-polyglutamic acid and a cell growth factor. The composition for preventing the xerophthalmia comprises an effective dosage of gamma-polyglutamic acid and the cell growth factor which are used as main active ingredients; and the active ingredients can be mutually complemented with each other on function, so that the xerophthalmia can be effectively prevented. The eye mask manufactured by the technical scheme can be widely applied to eye protection of people and is particularly applicable to eye protection of groups who look at computers for a long tine or work by other terminal displays, people who wear contact lenses and diabetes patients.
Description
Technical field
The present invention relates to the Applied Biotechnology field, in particular to a kind of compositions of preventing xerophthalmia, comprise the method for preparing of its eye patch and this eye patch.
Background technology
Popularizing and using of the Internet, computer and various terminal displays indicates the progress in epoch, makes people's work and living habit that huge variation take place, but also is accompanied by the serious day by day of people's eyes subhealth state problem simultaneously.The xerophthalmia sickness rate is constantly soaring to be one of them typical case.The xerophthalmia Epidemiological study shows; The sickness rate of general population's xerophthalmia is about 11～15%, but the sickness rate of the people of life-time service computer or other terminal display work, the people who wears contact lens and diabetes patient's xerophthalmia or doubtful xerophthalmia can be up to 80～90%.
According to incompletely statistics, three types of crowds below are badly in need of daily eye care:
1) personnel that utilize terminal display (computer) to work for a long time
According to the information that Information Office of the State Council announces in July, 2009, China's number of netizen has surpassed 3.3 hundred million people.Along with the Internet and informationalized popularizing, the personnel that the dependence terminal display carries out work constantly increase, and have brought serious problem also for simultaneously these people's eye health.An investigation report of U.S.'s whole nation occupational health and safety research institute shows, the person more than 3 hours that before computer, works every day, and 90% eyes have problem.Show that according to the investigation of China relevant department the surf time that 66.3% student average every day is arranged was above 3～4 hours.
The normal population xerophthalmia Epidemiological study that China carried out shows, general population's sickness rate about 11%, and Pekinese's number of patients maybe be about 2,000,000, and the white collar crowd has accounted for significant proportion.Have a investigation report to claim recently, the incidence rate of white collar clan's xerophthalmia is up to 100%.
2) wear the people of contact lens
Wear the people of contact lens, account for crowd's about 10% in developed country, estimate about 1% in China, number surpasses 13,000,000.EPDML survey result shows that the life-time service contact lens is suffered from xerophthalmia and cornea attenuation gradually easily.
The sanitary work NAB National Association 0f Broadcasters of Shanghai Yangpu District had once done investigation to 1500 undergraduate oculopathy situations of 7 colleges and universities such as Fudan University, Shanghai University Of Finance, Shanghai Aquatic Products Univ. 9CN), Shanghai University Of Sport.Find that malaise symptoms such as the canthus is dry and astringent, eyeglass adhesion precipitate, ocular infection, inflammation have appearred in 80% contact lens wear person in various degree.The university students of active treatment oculopathy is for counting seldom consciously.
3) diabetics
EPDML investigation shows that diabetics xerophthalmia sickness rate is 37% to xerophthalmia, and China's diabetics has reached more than 9,200 ten thousand people at present.
In fact xerophthalmia has become a kind of high morbidity of harm people eye health.The group of people at high risk of xerophthalmia comprises the people of life-time service terminal display work, the people who wears contact lens, the patient who carried out ophthalmologic operation, diabetes patient and senile xerophthalmia etc., and its summation possibly surpass 300,000,000 people in China's conservative estimation.And this part philtrum overwhelming majority never initiatively has been hospital diagnosis or treatment.Even more serious is, comprises society culturally advanced as the U.S., still has xerophthalmia patient more than 75% always less than hospital therapy, has not also heard xerophthalmia.This present situation is pointed out us, and a kind of daily eye care care product to the prevention xerophthalmia possibly accepted by people than the medicine for treatment that obtains through hospital more easily, and the crowd of contact is more extensive.
Summary of the invention
The present invention aims to provide a kind of compositions of preventing xerophthalmia, comprises the method for preparing of its eye patch and this eye patch, a kind of daily eye care care product of the prevention xerophthalmia that people accepted that is more easily promptly is provided.
To achieve these goals, according to an aspect of the present invention, a kind of compositions of preventing xerophthalmia is provided.Said composition comprises the gamma-polyglutamic acid-and the cell growth factor of effective dose.
Further, cell growth factor is selected from one or more in the group of being made up of epidermal growth factor, acidity or basic fibroblast growth factor, keratinocyte growth factor.
Further, said composition comprises gamma-polyglutamic acid-0.01～1g/1000ml, the auxiliary element of growth factor-21～100 μ g/ml and liquid, preferably, gamma-polyglutamic acid-0.02～0.5g/1000ml.
Further, compositions comprises following component: gamma-polyglutamic acid-0.04～0.1g/1000ml, cell growth factor 4～20 μ g/ml; Glycerol 35～45g/1000ml; Mannitol 4～6g/1000ml, phosphate 0.8～1.2g/1000ml, propylparaben 0.2～0.3g/1000ml; Butoben 0.2～.3g/1000ml, and the water of surplus.
Further; Comprise following component: glycerol 40g/1000ml, mannitol 5g/1000ml, phosphate 1g/1000ml; Propylparaben 0.25g/1000ml, butoben 0.25g/1000ml; Gamma-polyglutamic acid-0.04～0.1g/1000ml, the water of cell growth factor 10～15 μ g/ml and surplus, the pH value of compositions is 6.8～7.2.
Further, cell growth factor derives from people, animal or plant; Cell growth factor is natural extract, artificial chemosynthesis, source of human stem cell or passes through the cell growth factor of gene recombination technology manufacturing or the derivant of cell growth factor.
Further, gamma-polyglutamic acid-is gamma-polyglutamic acid-natural extract, artificial chemosynthesis or that pass through the microbial fermentation manufacturing.
According to another aspect of the present invention, a kind of eye patch that prevents xerophthalmia is provided.This eye patch comprises the compositions and the inert solid support of above-mentioned prevention xerophthalmia.
Further, inert solid support is selected from the hydrogel of non-woven fabrics, filter paper, silk fabric, bacterial fibers film or chemosynthesis.
A kind of method for preparing of eye patch is provided according to a further aspect of the invention.This method may further comprise the steps: 1) packing inert solid support in the aluminium foil bag into, is to carry out irradiation under the condition of 4～15kGy at irradiation dose; 2) join the compositions of above-mentioned prevention xerophthalmia in the aluminium foil bag that inert solid support is housed, seal.
The compositions of prevention xerophthalmia of the present invention, (γ-PGA) is a main active with cell growth factor, and these active component can replenish each other on function, bring out the best in each other, and effectively prevent xerophthalmia to contain the gamma-polyglutamic acid-of effective dose.The eye patch of technical scheme manufacturing can be widely used in eye health care according to the present invention, be particularly suitable for using for a long time computer or other terminal display work the crowd, wear the people and the diabetes patient's of contact lens eye health.
The present invention is used in gamma-polyglutamic acid-in the prescription of eye care article first, and its active component and another kind of active component cell growth factor as the compositions of prevention xerophthalmia of the present invention is used, and makes its function replenish each other, bring out the best in each other.And these two types of materials are beat all to have a synergism, its effect that is used greater than its use separately add and effect.
Cell growth factor described in the present invention is the cell growth factor that the propagation of mice 3T3 cell is had tangible dose-dependence; Comprising but be not limited to epidermal growth factor (EGF), acidity or basic fibroblast growth factor (a/bFGF) and keratinocyte growth factor (KGF) etc.; These cell growth factor are the important cell growth regulators that contain in the healthy subjects tear; It is active to have widely promoting growth of cell, but on clinical medicine accelerated wound healing, improve healing quality.
A large amount of clinical medicine basic research show, thereby these cell growth factor play important effect (Ahmet Satici etc.: Ophthalmic Research2003 for the integrity of keeping corneal epithelium in the stability that keeps the tear film; 35:301-305).
Gamma-polyglutamic acid-among the present invention (γ-PGA) is the natural biological macromole that is polymerized by glutamic acid, have good biocompatibility, nontoxic, do not have immunogenicity, more stable than hyaluronic acid.
The gamma-polyglutamic acid-hydrogel has superpower moisture-keeping functions, and its moisture-retaining capacity is 500 times of hyaluronic acid (HA).Xerophthalmia patient is because of meibomian gland dysfunction, and the outer lipid layer of tear film is damaged, the tear film rupture, and water evaporates, thereby the tear osmotic pressure increases, its result causes corneal epithelial defect.The destruction of cornea integrity influences the stability of tear film again conversely, and this is the process of an interaction, vicious cycle, and the eye surface diseases that its final result will cause comprising xerophthalmia is on the rise.Therefore suitably increase tear moisture, keep the important means that the normal osmotic pressure of tear is the treatment xerophthalmia.The high moisture-keeping functions of gamma-polyglutamic acid-possibly have outstanding performance in this respect.
Gamma-polyglutamic acid-is the composition of some gram-positive bacterium (Bacillus sp) cell wall, is the product that forms antibacterial autoprotection mechanism, has antibiotic, antiviral function.
Gamma-polyglutamic acid-also has radiation-resisting functional.Though modern technologies have been reduced to the limit to the radiation dose of computer display screen, still have radiation to exist, this is true.The personnel of large quantities of dependence terminal display work, have to accept the year in year out injury of this integrated radiation dose of their eyes.This is the arch-criminal who causes white collar clan's xerophthalmia prevalence constantly soaring.Gamma-polyglutamic acid-can form natural protection barrier one at the eye table, easing down to minimum from the display screen radiation to the accumulation of eyes injury.
Gamma-polyglutamic acid-have with normal tear fluid in keep the similar physical and chemical character of main component mucin of tear membrane stability; Can be interpreted as the artificial mucin of external source to gamma-polyglutamic acid-, stability, the prolongation breakup time of tear film of keeping the tear film had assosting effect.
A kind of typical embodiment according to the present invention, the compositions of prevention xerophthalmia comprises the gamma-polyglutamic acid-and the cell growth factor of effective dose.Cell growth factor among the present invention includes but not limited to that cell growth factor is selected from one or more in the group of being made up of epidermal growth factor, acidity or basic fibroblast growth factor, keratinocyte growth factor.
Preferably, said composition comprises gamma-polyglutamic acid-0.01～1g/1000ml, the auxiliary element of growth factor-21～100 μ g/ml and liquid.Further preferably, gamma-polyglutamic acid-0.02～0.5g/1000ml, cell growth factor 2～50 μ g/ml.One go on foot preferably gamma-polyglutamic acid-0.03～0.2g/1000ml again.Further preferably, gamma-polyglutamic acid-0.04～0.1g/1000ml, cell growth factor 4～20 μ g/ml.
A kind of typical embodiment according to the present invention; Compositions comprises following component: glycerol 40g/1000ml, mannitol 5g/1000ml, phosphate 1g/1000ml; Propylparaben 0.25g/1000ml, butoben 0.25g/1000ml; Gamma-polyglutamic acid-0.04～0.1g/1000ml, the water of cell growth factor 10～15 μ g/ml and surplus, the pH value of compositions is 6.8～7.2.
Preferably; Cell growth factor among the present invention has tangible dose-dependence to the propagation of mice 3T3 cell; This cell growth factor has the growth and the differentiation that can promote corneal epithelial cell, conjunctiva goblet cell, lachrymal gland acinous cell and tarsal glands epithelial cell etc.; To keeping the Ultrastructural integrity of corneal epithelium, promote the secretion of tear, mucin and lipid, thereby the stability of maintenance tear film all has the effect of crucial biological function.
Cell growth factor among the present invention can be to come from people, animal or plant; Can be cell growth factor natural extract, artificial chemosynthesis, source of human stem cell or that make through gene recombination technology or the derivant of cell growth factor.
Gamma-polyglutamic acid-among the present invention can be natural extract, artificial chemosynthesis or pass through the gamma-polyglutamic acid-that microbial fermentation is made.This chemical compound can present single glutamic acid characteristic absorption peak with hydrochloric acid hydrolysis after C18 post high-pressure liquid phase separates.
Auxiliary element among the present invention includes but not limited to: glycerol, mannitol, phosphate etc.Glycerol, mannitol are used for the biological activity of stable composition cell growth factor in the present invention, and in the solution that contains glycerol, mannitol, the activity of cell growth factor can keep the long period in room temperature; Phosphate is used for the pH value of stable composition; Propylparaben, butyl ester are ophthalmic remedy antiseptic commonly used.
According to another aspect of the present invention, a kind of eye patch that prevents xerophthalmia is provided.This eye patch comprises the compositions and the inert solid support of above-mentioned prevention xerophthalmia, and compositions is immersed on the inert solid support.Inert solid support of the present invention includes but not limited to be selected from the hydrogel of non-woven fabrics, filter paper, silk fabric, bacterial fibers film or chemosynthesis.Eye patch of the present invention can directly be applied ointment or plaster on the eye surface.
According to a further aspect of the invention, a kind of eye patch method for preparing is provided.This method may further comprise the steps: 1) packing inert solid support in the aluminium foil bag into, is to carry out irradiation under the condition of 4～15kGy at irradiation dose; 2) join the compositions of above-mentioned prevention xerophthalmia in the aluminium foil bag that inert solid support is housed, seal.
The present invention has selected the combination of gamma-polyglutamic acid-and cell growth factor first when the treatment xerophthalmia, good synergism is arranged between the two, and the effect of adjuvant in addition makes the xerophthalmia agent that makes effectively improve the eyes sensation of dryness.
The specific embodiment
Need to prove that under the situation of not conflicting, embodiment and the characteristic among the embodiment among the present invention can make up each other.Specify the present invention below in conjunction with embodiment.
A kind of typical embodiment according to the present invention, eye patch is made up of two parts:
A part is to be main active and other complementary mixed solution that becomes to be grouped into cell growth factor with γ-PGA (gamma-polyglutamic acid-); It fills a prescription auxiliary element as follows: glycerol 40g/1000ml; Mannitol 5g/1000ml; Phosphate 1g/1000ml, propylparaben 0.25g/1000ml, butyl ester nipalgin 0.25g/1000ml, the water of surplus.The addition of γ-PGA is 0.4g/1000ml, and the addition of cell growth factor is 10～15 μ g/ml.In the eye patch prescription, autoclaving is afterwards quantitatively prepared, filtered to the auxiliary element except that γ-PGA and cell growth factor in proportion, γ-PGA and cell growth factor with 0.45 μ m membrane filtration degerming after in the adding auxiliary element.
Another part is an inert solid support, can be non-woven fabrics, filter paper, silk fabric, bacterial fibers film etc.Inert solid support is packed into and is sent irradiation sterilization in the aluminium foil bag, and irradiation dose is 4～15kGy.
Add the mixed solution for preparing and inert solid support is housed and in the aluminium foil bag of irradiation sterilization, every packed 3～5ml.Thermoplastic seals, and it is subsequent use to deposit in shady and cool place.
To combine embodiment to further specify beneficial effect of the present invention below.
The first step is by prescription 1 to 6 preparation mixed solution 1000ml.Glass container 6 cleanings adds by prescription:
Prescription 1
(wherein; EGF (epidermal growth factor) 5mg, FGF (fibroblast growth factor) 2.5mg, KGF (keratinocyte growth factor) 2.5mg)
Prescription 2
(wherein: EGF (epidermal growth factor) 10mg, FGF (fibroblast growth factor) 2.5mg, KGF (keratinocyte growth factor) 2.5mg)
Prescription 3
(wherein; EGF (epidermal growth factor) 5mg, FGF (fibroblast growth factor) 2.5mg, KGF (keratinocyte growth factor) 2.5mg)
Prescription 4
Prescription 5
Prescription 6
Except that γ-PGA and cell growth factor, quantitatively prepare, filter the back autoclaving in the prescription in proportion, γ-PGA and cell growth factor are during adding fills a prescription after with 0.45 μ m membrane filtration degerming.
Prescription 1 only is that the consumption of EGF is different, other composition and constant rate with the difference of prescription 2.Observed result shows that both effects do not have notable difference, explains that cell growth factor of the present invention can be in big concentration range use.The present invention implements by prescription 1.
Prescription 1 only is that the consumption of EGF is different, other composition and constant rate with the difference of prescription 2; Prescription 3 only adds compound cells somatomedin 10 μ g/ml, does not add γ-PGA, other composition and constant rate; Prescription 4 only adds γ-PGA0.04%, does not add the compound cells somatomedin, other composition and constant rate; Prescription 5 adds γ-PGA0.1%, does not add the compound cells somatomedin, other composition and constant rate.Observed result shows that prescription 1 does not have notable difference with the effect of prescription 2, explains that cell growth factor of the present invention can use in 10～100 μ g/ml concentration ranges.Prescription 3 does not have notable difference with the effect of prescription 4 yet, but has than notable difference with prescription 1 and prescription 2, and explaining between γ-PGA and compound cells somatomedin has good synergism.Prescription 5 does not have notable difference with prescription 4, explains that γ-PGA can use in 0.04～0.1% concentration range, and observed result is as shown in table 2 below.Prescription 6 does not add auxiliary materials such as glycerol, mannitol and phosphate, only is used to observe its stability under normal temperature condition.Room temperature is deposited after 2 months prescription 6 and is occurred muddy and with deposition, prescription 1～5 is observed down at same storage condition and similar phenomenon (table 1) do not occurred in 24 months, explains that auxiliary materials such as glycerol, mannitol and phosphate are necessity for the stability of keeping product.Wherein 3 examples in application example are used the eye patch of the prescription 1 after room temperature is deposited 24 months, and its effect does not have significant difference.Prescription 6 is not participated in the observation of trial effect.
Table 1. formulation stability is observed, MAIN OUTCOME MEASURES: whether solution is muddy, the appearance deposition
Filled a prescription 12345 6..............24 months
1～5 clarification clarification clarification clarification clarification clarification clarification
6 clarification turbidity and precipitations do not continue to observe
Have trial volunteer 821 people of obvious eyes sensation of dryness to participate in observation of the present invention, trial volunteer is divided into 5 groups at random, observe with the eye patch that contains above-mentioned 1～5 compound composition respectively, it is following to the observed result of improving the eyes sensation of dryness:
Table 2
| Prescription | Trial volunteer | Conscious improver | Effective percentage % |
| 1 | 156 | 149 | 95.5 |
| 2 | 201 | 189 | 94 |
| 3 | 129 | 92 | 71.3 |
| 4 | 172 | 143 | 83.1 |
| 5 | 163 | 129 | 79.1 |
According to the observation to above-mentioned 5 groups of trial volunteer trial effects, the present invention implements by prescription 1.
In second step, pack inert solid support in the aluminium foil bag into every packed two.Send irradiation center irradiation sterilization, irradiation dose is 4～15kGy.
The 3rd step joined the mixed solution for preparing in the aluminium foil bag that inert solid support is housed, every bag of 3～5ml, and it is subsequent use to deposit in shady and cool place after thermoplastic seals.
Application example
Trial volunteer: the age is from 18～65 years old men and women, the people dry and astringent with eyes, that photophobia is itched that foreign body sensation is arranged, the eyestrain is prone to typical dry eye symptoms such as shedding tears.Method for using: 1, thoroughly clean face by the daily method that washes one's face, particularly circumference of eyes cleans up; 2, tear Fresco Bag, taking out bubble has the eye patch of mixed solution of the present invention, and applies ointment or plaster on eye-cap, and extrusion lamination is close on the eye-cap it gently, takes off after about 20 minutes; 3, apply once every day, and noon or evening all can.Continuous 3～5 days, observed result.
Application example 1
The temperature so-and-so, the man, 18 years old, reading the high school senior, computer commonly used is consulted reference material.Subjective symptoms: foreign body sensation is itched, had to eyes, and observe and be covered with the blood streak around the cornea.Use at the of the present invention eye patch of room temperature preservation after 24 months after 3 days said symptom complete obiteration by guide of the present invention.
Application example 2
Chen, the man, 56 years old, certain city civil servant suffered from diabetes, hypertension etc.Subjective symptoms: eyes are dry and astringent, the photophobia of itching is shed tears.Used eye patch 5 days by guide of the present invention, said symptom complete obiteration.
Application example 3
Deng, the woman, 45 years old, certain city civil servant once wore contact lens, the near-sighted femtosecond laser corrective procedure of back row.Subjective symptoms: eyes are dry and astringent, foreign body sensation is arranged.Pressed the of the present invention eye patch of guide use of the present invention after room temperature is preserved 24 months 4 days, said symptom complete obiteration.
Application example 4
Suddenly so-and-so, the woman, 35 years old, certain programmer of computer company, the time of using computer work every day is at least above 8 hours.Subjective symptoms: eyes are dry and astringent, foreign body sensation is arranged, itch and shed tears.Used eye patch 3 days by guide of the present invention, said symptom complete obiteration.
Application example 5
The week so-and-so, the woman, 28 years old, certain bank clerk used the terminal display working time at least above 6 hours every day.Subjective symptoms: eyes are dry and astringent, photophobia is itched sheds tears.Used eye patch 3 days by guide of the present invention, said symptom complete obiteration.
Application example 6
What so-and-so, the man, 30 years old, certain company procedure manager, the time of using computer work every day is at least above 8 hours.Subjective symptoms: eyes are dry and astringent, foreign body sensation is arranged, itch and shed tears.Used eye patch 4 days by guide of the present invention, said symptom complete obiteration.
Application example 7
Zheng, the man, 55 years old, certain large-scale warehouse keeper of company, the time of using computer work every day is at least above 5 hours.Subjective symptoms: eyes are dry and astringent, foreign body sensation is arranged, itch and shed tears.Used eye patch 5 days by guide of the present invention, said symptom complete obiteration.
Application example 8
Zeng, the woman, 40 years old, certain university teacher wore contact lens.Subjective symptoms: eyes are dry and astringent, foreign body sensation is arranged, itch and shed tears.Used eye patch 5 days by guide of the present invention, said symptom complete obiteration.
Application example 9
Tan, the man, 65 years old, the chief scientific research official of certain large-scale listed company, the time of using computer work every day is at least above 8 hours.Subjective symptoms: eyes are dry and astringent, foreign body sensation is arranged, itch and shed tears.Used eye patch 5 days by guide of the present invention, said symptom complete obiteration.
Application example 10
Guo so-and-so, the woman, 60 years old, the retired worker, row breast carcinoma excision is performed the operation with chemotherapy.Subjective symptoms after a period of time: eyes are dry and astringent, foreign body sensation is arranged, itch and shed tears.Pressed the of the present invention eye patch of guide use of the present invention after room temperature is preserved 24 months 5 days, said symptom complete obiteration.
The above is merely the preferred embodiments of the present invention, is not limited to the present invention, and for a person skilled in the art, the present invention can have various changes and variation.All within spirit of the present invention and principle, any modification of being done, be equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (11)
1. a compositions of preventing xerophthalmia is characterized in that, comprises the gamma-polyglutamic acid-and the cell growth factor of effective dose.
2. compositions according to claim 1 is characterized in that said cell growth factor is selected from one or more in the group of being made up of epidermal growth factor, acidity or basic fibroblast growth factor, keratinocyte growth factor.
3. compositions according to claim 1 is characterized in that, further comprises gamma-polyglutamic acid-0.01～1g/1000ml; The auxiliary element of growth factor-21～100 μ g/ml and liquid; Preferably, gamma-polyglutamic acid-0.02～0.5g/1000ml, cell growth factor 2～50 μ g/ml.
4. compositions according to claim 3 is characterized in that, said compositions comprises following component: gamma-polyglutamic acid-0.04～0.1g/1000ml, cell growth factor 4～20 μ g/ml.
5. compositions according to claim 2 is characterized in that, comprises following component; Gamma-polyglutamic acid-0.04～0.1g/1000ml; Cell growth factor 4～20 μ g/ml, glycerol 35～45g/1000ml, mannitol 4～6g/1000ml; Phosphate 0.8～1.2g/1000ml; Propylparaben 0.2～0.3g/1000ml, butoben 0.2～.3g/1000ml, and the water of surplus.
6. compositions according to claim 5 is characterized in that, comprises following component: glycerol 40g/1000ml; Mannitol 5g/1000ml, phosphate 1g/1000ml, propylparaben 0.25g/1000ml; Butoben 0.25g/1000ml; Gamma-polyglutamic acid-0.04～0.1g/1000ml, the water of said cell growth factor 10～15 μ g/ml and surplus, the pH value of said compositions is 6.8～7.2.
7. compositions according to claim 1 is characterized in that said cell growth factor derives from people, animal or plant; Said cell growth factor is natural extract, artificial chemosynthesis, source of human stem cell or passes through the cell growth factor of gene recombination technology manufacturing or the derivant of said cell growth factor.
8. compositions according to claim 1 is characterized in that, said gamma-polyglutamic acid-is gamma-polyglutamic acid-natural extract, artificial chemosynthesis or that pass through the microbial fermentation manufacturing.
9. an eye patch that prevents xerophthalmia is characterized in that, comprises compositions and inert solid support like each described prevention xerophthalmia in the claim 1 to 8.
10. eye patch according to claim 9 is characterized in that, said inert solid support is selected from the hydrogel of non-woven fabrics, filter paper, silk fabric, bacterial fibers film or chemosynthesis.
11. the method for preparing like claim 9 or 10 described eye patch is characterized in that, may further comprise the steps:
1) packing inert solid support in the aluminium foil bag into, is to carry out irradiation under the condition of 4～15kGy at irradiation dose;
2) join compositions in the aluminium foil bag that said inert solid support is housed, seal like each described prevention xerophthalmia in the claim 1 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210204557.8A CN102688479B (en) | 2012-06-20 | 2012-06-20 | Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210204557.8A CN102688479B (en) | 2012-06-20 | 2012-06-20 | Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102688479A true CN102688479A (en) | 2012-09-26 |
| CN102688479B CN102688479B (en) | 2014-07-09 |
Family
ID=46854322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210204557.8A Active CN102688479B (en) | 2012-06-20 | 2012-06-20 | Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102688479B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018232745A1 (en) * | 2017-06-23 | 2018-12-27 | 珠海亿胜生物制药有限公司 | Method for producing soluble recombinant human-basic fibroblast growth factor (rh-bfgf) |
| CN110151690A (en) * | 2019-07-03 | 2019-08-23 | 上海美哈医药科技有限公司 | A kind of eye-care collyrium and preparation method thereof |
| CN112094582A (en) * | 2019-06-17 | 2020-12-18 | 晶硕光学股份有限公司 | Contact lens solution capable of increasing moist feeling and contact lens product containing same |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006327949A (en) * | 2005-05-23 | 2006-12-07 | Hiroshi Takeda | Ophthalmic composition |
| WO2009088119A1 (en) * | 2008-01-07 | 2009-07-16 | Bioleaders Corporation | Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid |
| CN101721358A (en) * | 2009-05-18 | 2010-06-09 | 长春格鲁斯特生物科技有限公司 | Eye drops containing recombinant human keratinocyte growth factor-2 and application thereof in treating xeroma |
| CN101939363A (en) * | 2008-02-06 | 2011-01-05 | 东丽株式会社 | Aqueous dispersion containing polysaccharide particulate gel and method for producing the same |
| CN102266445A (en) * | 2011-07-22 | 2011-12-07 | 佘志坚 | Eye protection Chinese medicinal composition with health care and treatment effects |
| CN102357243A (en) * | 2011-11-02 | 2012-02-22 | 珠海亿胜生物制药有限公司 | Recombinant cattle basic fibroblastic growth factor eye drops |
-
2012
- 2012-06-20 CN CN201210204557.8A patent/CN102688479B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006327949A (en) * | 2005-05-23 | 2006-12-07 | Hiroshi Takeda | Ophthalmic composition |
| WO2009088119A1 (en) * | 2008-01-07 | 2009-07-16 | Bioleaders Corporation | Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid |
| CN101939363A (en) * | 2008-02-06 | 2011-01-05 | 东丽株式会社 | Aqueous dispersion containing polysaccharide particulate gel and method for producing the same |
| CN101721358A (en) * | 2009-05-18 | 2010-06-09 | 长春格鲁斯特生物科技有限公司 | Eye drops containing recombinant human keratinocyte growth factor-2 and application thereof in treating xeroma |
| CN102266445A (en) * | 2011-07-22 | 2011-12-07 | 佘志坚 | Eye protection Chinese medicinal composition with health care and treatment effects |
| CN102357243A (en) * | 2011-11-02 | 2012-02-22 | 珠海亿胜生物制药有限公司 | Recombinant cattle basic fibroblastic growth factor eye drops |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018232745A1 (en) * | 2017-06-23 | 2018-12-27 | 珠海亿胜生物制药有限公司 | Method for producing soluble recombinant human-basic fibroblast growth factor (rh-bfgf) |
| KR20200020900A (en) * | 2017-06-23 | 2020-02-26 | 주하이 에섹스 바이오-파머슈티컬 코., 엘티디. | Methods of Making Soluble Recombinant Human-Based Fibroblast Growth Factor (rh-bFGF) |
| CN110945123A (en) * | 2017-06-23 | 2020-03-31 | 珠海亿胜生物制药有限公司 | Method for producing soluble recombinant human basic fibroblast growth factor (rh-bFGF) |
| JP2020533014A (en) * | 2017-06-23 | 2020-11-19 | 珠海億勝生物製薬有限公司 | Method for Producing Soluble Recombinant Human Basic Fibroblast Growth Factor (rh-bFGF) |
| US11248032B2 (en) | 2017-06-23 | 2022-02-15 | Zhuhai Essex Bio-Pharmaceutical Co., Ltd. | Method for producing soluble recombinant human-basic fibroblast growth factor (rh-bFGF) |
| JP7098724B2 (en) | 2017-06-23 | 2022-07-11 | 珠海億勝生物製薬有限公司 | Method for Producing Soluble Recombinant Human Basic Fibroblast Growth Factor (rh-bFGF) |
| KR102428209B1 (en) * | 2017-06-23 | 2022-08-02 | 주하이 에섹스 바이오-파머슈티컬 코., 엘티디. | Method for making soluble recombinant human-basic fibroblast growth factor (rh-bFGF) |
| CN112094582A (en) * | 2019-06-17 | 2020-12-18 | 晶硕光学股份有限公司 | Contact lens solution capable of increasing moist feeling and contact lens product containing same |
| CN110151690A (en) * | 2019-07-03 | 2019-08-23 | 上海美哈医药科技有限公司 | A kind of eye-care collyrium and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102688479B (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012203398B2 (en) | Opthalmic compositions and methods for treating eyes | |
| Vogel et al. | Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena) | |
| CN107405360B (en) | Novel iodophor compositions and methods of use thereof | |
| CN107375032B (en) | Composition for repairing skin barrier and preparation method thereof | |
| CN107184427A (en) | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid | |
| CN111991415A (en) | Eye care composition and preparation method and application thereof | |
| BRPI0710615A2 (en) | methods and compositions for the treatment of infectious or infectious colonization of the eyelid, ocular surface, skin or ear | |
| KR20090031609A (en) | Methods and compositions for the treatment and prevention of infections | |
| Gallagher et al. | Development of a poly-ε-lysine contact lens as a drug delivery device for the treatment of fungal keratitis | |
| CN106265768B (en) | Cordyceps cicadae active substance, preparation method thereof, pharmaceutical composition containing cordyceps cicadae active substance and application of cordyceps cicadae active substance | |
| US20100184664A1 (en) | Ophthalmic compositions useful for improving visual acuity | |
| CN114588065A (en) | Ophthalmic composition and preparation method and application thereof | |
| CN102688479B (en) | Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask | |
| Basir et al. | Anticaries activity of curcumin on decay process in human tooth enamel samples (in vitro study) | |
| CN108697635A (en) | Ophthalmic composition for treating eye disease related with kerato-conjunctival surface modification | |
| CN103249419B (en) | There is antibacterial and wound healing activity compositions | |
| CN111317675B (en) | Acne removing composition containing D-panthenol, application of acne removing composition and cosmetics containing composition | |
| CN105899221A (en) | Dermatological composition based on algae and olive leaf extracts | |
| US20170239307A1 (en) | Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies | |
| CN104136005A (en) | Ophthalmic compositions with alkoxylated natural waxes | |
| CN106265720A (en) | A kind of combined artificial tear and preparation method thereof | |
| CN108852944A (en) | It is a kind of using OPC as tridecanoic peptide antibacterial repair latex of carrier and preparation method thereof | |
| CN103040735A (en) | Spirulina polysaccharide eye drop | |
| EP3682867A1 (en) | Lutein-containing ophthalmic composition | |
| RU2778503C1 (en) | Composition for hygienic treatment of the eyelids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: DENG HUIPING Effective date: 20131016 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20131016 Address after: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Applicant after: Tu Guihong Applicant after: Deng Huiping Address before: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Applicant before: Tu Guihong |
|
| ASS | Succession or assignment of patent right |
Owner name: DENG HUIPING SUN YUNWEN Free format text: FORMER OWNER: DENG HUIPING Effective date: 20140603 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140603 Address after: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Applicant after: Tu Guihong Applicant after: Deng Huiping Applicant after: Sun Yunwen Address before: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Applicant before: Tu Guihong Applicant before: Deng Huiping |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120926 Assignee: Guangzhou gold source Biotechnology Co., Ltd. Assignor: Sun Yunwen|Tu Guihong|Deng Huiping Contract record no.: 2015440000209 Denomination of invention: Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask Granted publication date: 20140709 License type: Common License Record date: 20150610 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Guangzhou Sino US Biotechnology Co., Ltd. Assignor: Tu Guihong|Deng Huiping|Sun Yunwen Contract record no.: 2015440000270 Date of cancellation: 20150619 Assignee: Guangzhou gold source Biotechnology Co., Ltd. Assignor: Sun Yunwen|Tu Guihong|Deng Huiping Contract record no.: 2015440000209 Date of cancellation: 20150619 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120926 Assignee: Guangzhou Sino US Biotechnology Co., Ltd. Assignor: Tu Guihong|Deng Huiping|Sun Yunwen Contract record no.: 2015440000270 Denomination of invention: Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask Granted publication date: 20140709 License type: Common License Record date: 20150617 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120926 Assignee: Guangzhou gold source Biotechnology Co., Ltd. Assignor: Tu Guihong|Deng Huiping|Sun Yunwen Contract record no.: 2015440000358 Denomination of invention: Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask Granted publication date: 20140709 License type: Exclusive License Record date: 20150623 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160408 Address after: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Patentee after: Tu Guihong Patentee after: Deng Huiping Address before: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Patentee before: Tu Guihong Patentee before: Deng Huiping Patentee before: Sun Yunwen |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Guangzhou gold source Biotechnology Co., Ltd. Assignor: Tu Guihong|Deng Huiping|Sun Yunwen Contract record no.: 2015440000358 Date of cancellation: 20160823 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160907 Address after: 510000 Guangdong province Guangzhou Science City, Guangzhou hi tech Industrial Development Zone, No. 31 Southern China new material Ke Feng Lu Creative Park G10 Building No. 501 Patentee after: Guangzhou gold source Biotechnology Co., Ltd. Address before: 510224 health industry incubation base of Guangzhou University City, Guangdong province 201-204 Patentee before: Tu Guihong Patentee before: Deng Huiping |